Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
JP Sevilla, Daria Burnes, Rehab Zakaria El Saie, Hammam Haridy, Matt Wasserman, Sarah Pugh, Johnna Perdrizet & David Bloom. (2022) Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt. Human Vaccines & Immunotherapeutics 18:6.
Read now
Read now
Johnna Perdrizet, Carlos Felipe S. Santana, Thais Senna, Rodrigo Fernandes Alexandre, Rodrigo Sini de Almeida, Julia Spinardi & Matt Wasserman. (2022) Reply letter to “response to article by Johnna Perdrizet et al.” by Gomez and colleagues. Human Vaccines & Immunotherapeutics 18:1.
Read now
Read now
Tufail M. Malik, Jemal Mohammed-Awel, Abba B. Gumel & Elamin H. Elbasha. (2021) Mathematical assessment of the impact of cohort vaccination on pneumococcal carriage and serotype replacement. Journal of Biological Dynamics 15:sup1, pages S214-S247.
Read now
Read now
Johnna Perdrizet, Carlos Felipe S. Santana, Thais Senna, Rodrigo Fernandes Alexandre, Rodrigo Sini de Almeida, Julia Spinardi & Matt Wasserman. (2021) Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants. Human Vaccines & Immunotherapeutics 17:4, pages 1162-1172.
Read now
Read now
Asrul Akmal Shafie, Norazah Ahmad, Jerusha Naidoo, Chee Yoong Foo, Callix Wong, Sarah Pugh & Kah Kee Tan. (2020) Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation. Human Vaccines & Immunotherapeutics 16:7, pages 1719-1727.
Read now
Read now
Matt Wasserman, Maria Gabriela Palacios, Ana Gabriela Grajales, Michele Wilson, Cheryl McDade & Raymond Farkouh. (2019) Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”. Human Vaccines & Immunotherapeutics 15:3, pages 572-574.
Read now
Read now
Jorge A. Gómez, Adriana Guzman Holst & Javier Nieto. (2019) Response to article by Matthew Wasserman et al. (2018): “Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico”. Human Vaccines & Immunotherapeutics 15:3, pages 570-571.
Read now
Read now
Articles from other publishers (12)
Michele Wilson, Cheryl McDade, Anna Trisia Beby-Heijtel, Angela Waterval-Overbeek, Vishalini Sundaram & Johnna Perdrizet. (2023) Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands. Infectious Diseases and Therapy 12:7, pages 1809-1821.
Crossref
Crossref
M. Sakil Syeed, Priyanka Ghule, Lan M. Le, Sajesh K. Veettil, Emily K. Horn, Johnna Perdrizet, Matt Wasserman, Ammarin Thakkinstian & Nathorn Chaiyakunapruk. (2023) Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies. Value in Health 26:4, pages 598-611.
Crossref
Crossref
Liping Huang, Cheryl L. McDade, Johnna E. Perdrizet, Michele R. Wilson, Sophie A. Warren, Susan Nzenze & Renilla Sewdas. (2023) Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease. Infectious Diseases and Therapy 12:3, pages 933-950.
Crossref
Crossref
Mark H. Rozenbaum, Johnna Perdrizet, Xiuyan Li, Matt D. Wasserman, Lindsay R. Grant, Kyla Hayford & Raymond A. Farkouh. (2022) A Response to: Letter to the Editor Regarding ‘Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age’. Infectious Diseases and Therapy 12:1, pages 295-298.
Crossref
Crossref
Johnna Perdrizet, Emily Horn, Winniefer Nua, Judith Perez-Peralta, Jennifer Nailes, Jaime Santos & Anna Ong-Lim. (2022) Response to Gomez et al.’s Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”. Infectious Diseases and Therapy.
Crossref
Crossref
Matt D. Wasserman, Johnna Perdrizet, Lindsay Grant, Kyla Hayford, Shubhra Singh, Paranjoy Saharia, Emily K. Horn & Raymond A. Farkouh. (2021) Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age. Infectious Diseases and Therapy 10:4, pages 2701-2720.
Crossref
Crossref
Johnna Perdrizet, Emily K. Horn, Winniefer Nua, Judith Perez-Peralta, Jennifer Nailes, Jaime Santos & Anna Ong-Lim. (2021) Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants. Infectious Diseases and Therapy 10:4, pages 2625-2642.
Crossref
Crossref
Mercedes Macias Parra, Isabel Medina-Vera, Eduardo Arias De la Garza, Miguel A. Rodriguez Weber & Ximena León-Lara. (2021) The Impact of Haemophilus Influenzae and Streptococcus Pneumoniae Vaccination in Bacterial Meningitis in a Pediatric Referral Hospital in Mexico. Journal of Pediatric Infectious Diseases 16:05, pages 230-236.
Crossref
Crossref
Michele R. Wilson, Cheryl L. McDade, Johnna E. Perdrizet, Annick Mignon, Raymond A. Farkouh & Matt D. Wasserman. (2021) Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium. Infectious Diseases and Therapy 10:3, pages 1765-1778.
Crossref
Crossref
Robert Root-Bernstein. (2021) Pneumococcal and Influenza Vaccination Rates and Pneumococcal Invasive Disease Rates Set Geographical and Ethnic Population Susceptibility to Serious COVID-19 Cases and Deaths. Vaccines 9:5, pages 474.
Crossref
Crossref
Johnna Perdrizet, Yuen S. Lai, Scott Williams, Valda A. Struwig & Matt Wasserman. (2021) Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia. Infectious Diseases and Therapy 10:1, pages 507-520.
Crossref
Crossref
Filippo Ansaldi, Sarah Pugh, Daniela Amicizia, Roberto Di Virgilio, Cecilia Trucchi, Andrea Orsi, Alessandro Zollo & Giancarlo Icardi. (2020) Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy. Pathogens 9:2, pages 76.
Crossref
Crossref